Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease.

Citation metadata

Date: May 17, 2021
Publisher: Frontiers Research Foundation
Document Type: Article
Length: 424 words
Lexile Measure: 1540L

Document controls

Main content

Article Preview :

Author(s): Qianqian Li, Xiao Ding, Yujie Liu, Cicilia Marcella, Min Dai, Ting Zhang, Jianling Bai, Liyuan Xiang, Quan Wen, Bota Cui, Faming Zhang

<bold>Background:</bold> How to handle patients with anti-tumor necrosis factor (anti-TNF) failure was a common challenge to clinicians in Crohn's disease (CD). The present study is dedicated to clarifying whether fecal microbiota transplantation (FMT) could be a switch therapy for patients with prior failure of infiiximab (IFX) in CD in a long-term observation.

<bold>Methods:</bold> Thirty-six patients with CD who had prior failure of IFX were recruited from January 2013 to December 2019. The "one-hour FMT protocol" was followed in all patients. All patients received...

Source Citation

Source Citation   

Gale Document Number: GALE|A662032825